Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1916 1
1946 1
1955 1
1957 1
1962 5
1963 8
1964 4
1965 6
1966 6
1967 11
1968 6
1969 7
1970 4
1971 4
1972 9
1973 13
1974 5
1975 5
1976 13
1977 13
1978 13
1979 15
1980 24
1981 17
1982 13
1983 16
1984 23
1985 27
1986 18
1987 22
1988 18
1989 19
1990 20
1991 31
1992 36
1993 19
1994 18
1995 23
1996 15
1997 16
1998 19
1999 18
2000 28
2001 37
2002 45
2003 43
2004 61
2005 87
2006 91
2007 104
2008 98
2009 105
2010 147
2011 138
2012 175
2013 207
2014 206
2015 228
2016 222
2017 240
2018 258
2019 260
2020 310
2021 359
2022 371
2023 282

Text availability

Article attribute

Article type

Publication date

Search Results

4,193 results

Results by year

Filters applied: . Clear all
Page 1
A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma.
Pal S, Kaplan JP, Nguyen H, Stopka SA, Savani MR, Regan MS, Nguyen QD, Jones KL, Moreau LA, Peng J, Dipiazza MG, Perciaccante AJ, Zhu X, Hunsel BR, Liu KX, Alexandrescu S, Drissi R, Filbin MG, McBrayer SK, Agar NYR, Chowdhury D, Haas-Kogan DA. Pal S, et al. Cancer Cell. 2022 Sep 12;40(9):957-972.e10. doi: 10.1016/j.ccell.2022.07.012. Epub 2022 Aug 18. Cancer Cell. 2022. PMID: 35985342 Free PMC article.
VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system.
So J, Mabe NW, Englinger B, Chow KH, Moyer SM, Yerrum S, Trissal MC, Marques JG, Kwon JJ, Shim B, Pal S, Panditharatna E, Quinn T, Schaefer DA, Jeong D, Mayhew DL, Hwang J, Beroukhim R, Ligon KL, Stegmaier K, Filbin MG, Hahn WC. So J, et al. Among authors: pal s. JCI Insight. 2022 Oct 10;7(19):e158755. doi: 10.1172/jci.insight.158755. JCI Insight. 2022. PMID: 36040810 Free PMC article.
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Dubey S, Bex A. Pal SK, et al. Lancet. 2022 Oct 1;400(10358):1103-1116. doi: 10.1016/S0140-6736(22)01658-0. Epub 2022 Sep 10. Lancet. 2022. PMID: 36099926 Clinical Trial.
RNA-Binding Macrocyclic Peptides.
Pal S, 't Hart P. Pal S, et al. Front Mol Biosci. 2022 Apr 19;9:883060. doi: 10.3389/fmolb.2022.883060. eCollection 2022. Front Mol Biosci. 2022. PMID: 35517859 Free PMC article. Review.
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM. Rini BI, et al. Among authors: pal sk. J Immunother Cancer. 2022 Dec;10(12):e005445. doi: 10.1136/jitc-2022-005445. J Immunother Cancer. 2022. PMID: 36549781 Free PMC article. Clinical Trial.
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Agarwal N, et al. Among authors: pal s. Lancet Oncol. 2022 Jul;23(7):899-909. doi: 10.1016/S1470-2045(22)00278-9. Epub 2022 Jun 9. Lancet Oncol. 2022. PMID: 35690072 Clinical Trial.
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.
Pal SK, Somford DM, Grivas P, Sridhar SS, Gupta S, Bellmunt J, Sonpavde G, Fleming MT, Lerner SP, Loriot Y, Hoffman-Censits J, Valderrama BP, Andresen C, Schnabel MJ, Cole S, Daneshmand S. Pal SK, et al. Future Oncol. 2022 Jul;18(21):2599-2614. doi: 10.2217/fon-2021-1629. Epub 2022 May 24. Future Oncol. 2022. PMID: 35608106 Free article. Review.
Defining the Mycobiome in Bladder Cancer.
Mercier BD, Castro DV, Pal SK. Mercier BD, et al. Among authors: pal sk. Eur Urol Open Sci. 2022 Dec 27;48:70-71. doi: 10.1016/j.euros.2022.11.023. eCollection 2023 Feb. Eur Urol Open Sci. 2022. PMID: 36606201 Free PMC article. No abstract available.
4,193 results